Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17920313 | 0.90 | ROCK2 (0.52) | ROCK2 | |
| SCHEMBL17912940 | 0.88 | ROCK2 (0.56) | ROCK2 | |
| SCHEMBL17912977 | 0.87 | ROCK2 (0.57) | ROCK2 | |
| SCHEMBL19759537 | 0.86 | ROCK2 (0.57) | ROCK2 | |
| SCHEMBL17920298 | 0.84 | ROCK2 (0.57) | ROCK2 | |
| SCHEMBL17913006 | 0.79 | ROCK2 (0.51) | ROCK2 | |
| SCHEMBL19759535 | 0.78 | ROCK2 (0.63) | ROCK2 | |
| SCHEMBL17920301 | 0.78 | ROCK2 (0.56) | ROCK2 | |
| SCHEMBL22227644 | 0.77 | ROCK2 (0.60) | ROCK2 | |
| SCHEMBL17920292 | 0.77 | ROCK2 (0.53) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | claimed |
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10123993-B2 | Cyclic ureas as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3242873-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123993-B2 | Cyclic ureas as inhibitors of rock | MYLK, ROCK1, UACA | ROCK2 4/4885 |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | MYLK, ROCK1, UACA | ROCK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.